Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 13/20 | 0.61 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17034791 | 0.89 | ALDH1A1 (0.61) | ALDH1A1EPHX2EPHX1LMNANPSR1 | |
| SCHEMBL12136850 | 0.84 | EPHX2 (0.57) | ALDH1A1EPHX2EPHX1 | |
| SCHEMBL23059414 | 0.81 | ALDH1A1 (0.50) | ALDH1A1EPHX2EPHX1LMNANPSR1 | |
| SCHEMBL12612604 | 0.81 | ALDH1A1 (0.64) | ALDH1A1LMNANPSR1CA12CA1 | |
| SCHEMBL4925631 | 0.81 | EPHX2 (0.69) | ALDH1A1EPHX2EPHX1 | |
| SCHEMBL9893075 | 0.80 | EPHX2 (0.67) | EPHX2EPHX1 | |
| SCHEMBL10200817 | 0.80 | EPHX1 (0.68) | ALDH1A1EPHX2EPHX1LMNANPSR1 | |
| SCHEMBL4087474 | 0.80 | ALDH1A1 (0.60) | ALDH1A1EPHX2EPHX1LMNANPSR1 | |
| SCHEMBL21100016 | 0.80 | ALDH1A1 (0.60) | ALDH1A1EPHX2EPHX1LMNANPSR1 | |
| SCHEMBL14263081 | 0.79 | ALDH1A1 (0.62) | ALDH1A1EPHX2EPHX1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142677-A1 | Pyrrolidine Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 3279/4885EPHX2 2014/4885EPHX1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.